Transplanting healthy mitochondria shows real biological signals — but clinical benefit is not yet reproducibly shown, a new review concludes

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Few ideas in mitochondrial medicine are as compelling — or as easy to oversell — as transplanting the organelles themselves. This review draws the line between what the experiments show and what clinics can claim.

What did the review examine?

The evidence for delivering intact, respiration-competent exogenous mitochondria as a therapy for ischemia-reperfusion injury — the tissue damage that follows restored blood flow in heart attack, stroke, transplantation and similar settings. The synthesis spans cellular systems, isolated perfused organs, animal models, and the first patient studies, including a 2026 open-label phase I study in four patients with acute cerebral ischemia alongside twelve retrospective matched controls, designed for safety and feasibility.

What is the honest bottom line?

Two-sided. On one side, biological effects are consistent across preclinical models — transplanted mitochondria can improve bioenergetics and salvage tissue. On the other, the effect is not a simple dose story: it depends on the functional state of the mitochondrial preparation and on effective exposure of the target organ, and neither particle count nor protein content alone predicts it. In patients, the evidence supports feasibility and early safety signals — not clinical efficacy, which the review states has not been reproducibly demonstrated.

Why does this matter now?

Because transplantation is moving from curiosity toward clinic, and preparation quality is becoming the deciding variable — the same week brought a methods advance in harvesting intact mitochondria at double yield in lab cells. Readers encountering clinic marketing for 'mitochondrial therapy' should ask which of those two evidence columns — preclinical signals or patient outcomes — any claim actually comes from.

Where the evidence stands

• Established: Ischemia-reperfusion injury involves acute mitochondrial failure, and delivering viable mitochondria produces measurable bioenergetic effects in laboratory and animal models.
• Preliminary: Tissue-salvage benefits in animal and organ models, and feasibility/early safety in very small early patient studies, as synthesised by one 2026 review.
• Absent: Reproducibly demonstrated clinical efficacy in patients — stated plainly by the review itself.